Core Viewpoint - Emergent BioSolutions Inc. reported a significant increase in net income and profitability margins for Q1 2025, despite a decline in total revenues compared to the previous year, indicating a successful execution of its strategic plan aimed at long-term growth and profitability [2][3][6]. Financial Highlights - Total revenues for Q1 2025 were $222.2 million, a decrease of 26% from $300.4 million in Q1 2024 [3][6]. - Net income surged to $68.0 million, reflecting a 656% increase from $9.0 million in Q1 2024 [3][6]. - Adjusted net income rose by 31% to $40.7 million, compared to $31.1 million in the prior year [3][6]. - Adjusted EBITDA increased by 16% to $77.6 million, with an adjusted EBITDA margin of 35%, up from 22% in Q1 2024 [3][6]. Revenue Breakdown - Product sales decreased by 26% to $201.9 million, with notable declines in NARCAN sales by 62% and Anthrax MCM by 14%, while Smallpox MCM sales increased by 112% [9][10][11][12]. - Revenues from services fell by 61% to $7.2 million, primarily due to the sale of the Camden facility [16]. - Contracts and grants revenue increased by 64% to $13.1 million, driven by development work related to Ebanga™ [17]. Operating Expenses - Total operating expenses decreased by 34% to $172.3 million, with significant reductions in cost of product and services sales by 39% and SG&A expenses by 38% [18][19][21]. - Research and development expenses remained stable at $15.1 million [20]. Recent Business Updates - The company secured contracts valued at approximately $20 million for BioThrax® supply to the U.S. Department of Defense and $16.7 million for collaboration on Ebanga™ [7]. - Emergent gained exclusive commercial rights to KLOXXADO in the U.S. and Canada and completed the sale of its Baltimore-Bayview facility for $36.5 million [7]. - The Board authorized a stock repurchase program of up to $50 million [7]. Financial Forecast - The company reaffirmed its 2025 financial guidance, expecting total revenues between $750 million and $850 million, with net income projected between $20 million and $70 million [31][32].

Core Viewpoint - Alto Ingredients, Inc. reported improved year-over-year gross margin and Adjusted EBITDA for Q1 2025, driven by operational efficiencies from its recent acquisition of Alto Carbonic and a corporate reorganization aimed at cost savings [2][4]. Financial Performance - Net sales for Q1 2025 were $226.5 million, down from $240.6 million in Q1 2024 [8][14]. - Cost of goods sold decreased to $228.3 million from $243.0 million, resulting in a gross loss of $1.8 million compared to a gross loss of $2.4 million in the previous year [8][14]. - Selling, general and administrative expenses were reduced to $7.2 million from $7.9 million [8][14]. - The net loss attributable to common stockholders was $12.0 million, or $0.16 per share, compared to a net loss of $12.0 million, or $0.17 per share, in the prior year [8][14]. Operational Highlights - The acquisition of Alto Carbonic has led to lower combined costs and improved operational coordination, contributing to an expected annual savings of approximately $8 million starting Q2 2025 [2][3]. - The company shifted production to ISCC renewable fuel for European markets, which is experiencing strong demand, partially offsetting the domestic softening of premiums on high-quality alcohol and essential ingredients [3][4]. Cash and Liquidity - Cash and cash equivalents were reported at $26.8 million as of March 31, 2025, down from $35.5 million at the end of 2024 [5][16]. - The company's borrowing availability stood at $76.7 million, including $11.7 million under the operating line of credit and $65.0 million under its term loan facility [5][16]. Market Metrics - Total renewable fuel gallons sold decreased to 65.3 million in Q1 2025 from 72.7 million in Q1 2024 [19]. - The average sales price per gallon for alcohol increased to $1.93 from $1.86 year-over-year [20]. - Essential ingredients sold totaled 310.8 thousand tons, slightly down from 313.4 thousand tons in the previous year [20].

Core Insights - OrthoPediatrics Corp. reported a 17% year-over-year increase in total revenue for Q1 2025, reaching $52.4 million compared to $44.7 million in Q1 2024 [4] - The company continues to focus on pediatric orthopedics, achieving significant growth in both U.S. and international markets [3][4] Financial Performance - Total revenue for Q1 2025 was $52.4 million, a 17% increase from $44.7 million in Q1 2024 [4] - U.S. revenue increased by 19% to $40.9 million, representing 78% of total revenue, while international revenue grew by 11% to $11.5 million, accounting for 22% of total revenue [4] - Trauma and Deformity revenue rose 14% to $37.9 million, and Scoliosis revenue surged 34% to $13.7 million [5][4] - Gross profit for Q1 2025 was $38.3 million, a 19% increase from $32.2 million in the same period last year, with a gross profit margin of 73% [6] Operating Expenses - Total operating expenses for Q1 2025 were $49.2 million, an 18% increase from $41.9 million in Q1 2024, primarily due to increased personnel and non-cash stock compensation [7][10] - Sales and marketing expenses rose by 17% to $16.6 million, driven by higher sales commissions [8] Profitability Metrics - The net loss for Q1 2025 was $10.7 million, compared to a net loss of $7.8 million in Q1 2024, with a net loss per share of $0.46 [11] - Adjusted EBITDA for Q1 2025 was a loss of $0.4 million, an improvement from a loss of $1.1 million in Q1 2024 [11][29] Cash Flow and Guidance - The company reduced free cash flow usage by 35% compared to the same period last year and anticipates achieving positive free cash flow in Q4 2025 [8] - Full-year 2025 revenue guidance was increased to between $236.0 million and $242.0 million, reflecting a growth of 15% to 18% compared to 2024 [13]

GAAP Net Income of $0.2 Million or $0.00 per Share; EBITDAR of $20.6 Million Revenue of $66.6 Million with Total Block Hours of 7,546 MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Global Crossing Airlines Group, Inc. (Cboe CA: JET, Cboe CA: JET.B, OTCQB: JETMF) (the "Company" or "GlobalX"), the Nation's fastest growing charter airline, today announced its financial and operating results for the first quarter ended March 31, 2025. Except as otherwise disclosed, all figures for the three-month period are presented ...

Three Months Ended March 31, 2025 Highlights AUSTIN, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Open Lending Corporation (Nasdaq: LPRO) (the "Company" or "Open Lending"), an industry trailblazer in lending enablement and risk analytics solutions for financial institutions, today reported financial results for its first quarter ended March 31, 2025. "I believe in Open Lending's business model, our value proposition to our customers, and the team's ability to execute on our plan going forward," said Jessica Buss ...

Core Insights - Green Thumb Industries reported a total revenue of $280 million for Q1 2025, reflecting a 1.4% increase from the same period last year [5][9] - The company experienced a decrease in overall retail revenue by 2.5% compared to Q1 2024, primarily due to price compression in existing markets [5][6] - Adjusted EBITDA for the quarter was $85 million, representing 31% of revenue, down from $90.5 million or 32.8% of revenue in Q1 2024 [11][9] Financial Performance - Gross profit for Q1 2025 was $143.3 million, accounting for 51.3% of revenue, compared to $144.9 million or 52.5% of revenue in Q1 2024 [7][9] - Total selling, general, and administrative expenses increased to $100.8 million, or 36.1% of revenue, from $74.3 million or 26.9% of revenue in the prior year [8][9] - Net income attributable to the company was $8.3 million, or $0.04 per share, a decrease from $31.1 million, or $0.13 per share, in the prior year [10][26] Business Developments - The company opened two new RISE Dispensaries during the quarter, including locations in Nevada and Ohio [9][15] - Green Thumb is preparing for the launch of adult-use sales in Minnesota, expected to commence before the end of the year [4] - The company introduced the Bud Ball event in New York City, expanding its brand presence in the lifestyle segment [4] Balance Sheet and Liquidity - As of March 31, 2025, Green Thumb had $211 million in cash and cash equivalents, with total current assets of $444.9 million [13][27] - Total debt outstanding was $252.4 million, consisting of approximately $150 million in senior secured debt and $100 million in real estate mortgages [13] - The company repurchased approximately 160,000 Subordinate Voting Shares for about $1 million during the first quarter [14]

Net Investment Income of $0.41 Per Share for Q1 2025; Investment Portfolio fair value: $2.0 billion | Comprehensive Investment Portfolio fair value: $3.1 billion Non-accruals: 0.4% at fair value, 0.6% at cost of Investment Portfolio Net assets: $990.5 million or $18.16 per share Leverage: 1.04x net debt-to-equity Declared Quarterly Distribution of $0.41 Per Share; Stable NAV/Strong Credit Quality NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- SLR Investment Corp. (NASDAQ: SLRC) (the "Company", "SLRC", "we", "us ...

At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs. Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today annou ...

CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Monroe Capital Corporation (NASDAQ: MRCC) today announced its financial results for the first quarter ended March 31, 2025. Except where the context suggests otherwise, the terms "Company," "we," "us," and "our" refer to Monroe Capital Corporation (together with its subsidiaries). First Quarter 2025 Financial Highlights Chief Executive Officer Theodore L. Koenig commented, "We are pleased to announce that we paid a $0.25 per share dividend during the first quarter r ...

Core Insights - Journey Medical Corporation will release its first quarter 2025 financial results on May 14, 2025, after U.S. financial markets close [1] - A conference call and audio webcast will be held on the same day at 4:30 p.m. ET to discuss the financial results and provide a corporate update [1] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription products for dermatological conditions [4] - The company currently markets eight FDA-approved prescription drugs and has a team of industry experts with extensive experience in dermatology [4] - Journey Medical is based in Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. [4]